Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study
Articolo
Data di Pubblicazione:
2017
Citazione:
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study / Sands, Be; Chen, Jj; Feagan, Bg; Penney, M; Rees, Wa; Danese, S; Higgins, Pdr; Newbold, P; Faggioni, R; Patra, K; Li, J; Klekotka, P; Morehouse, C; Pulkstenis, E; Drappa, J; van der Merwe, R; Gasser, Ra. - In: GASTROENTEROLOGY. - ISSN 0016-5085. - 153:1(2017), pp. 77-+. [10.1053/j.gastro.2017.03.049]
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Sands, Be; Chen, Jj; Feagan, Bg; Penney, M; Rees, Wa; Danese, S; Higgins, Pdr; Newbold, P; Faggioni, R; Patra, K; Li, J; Klekotka, P; Morehouse, C; Pulkstenis, E; Drappa, J; van der Merwe, R; Gasser, Ra
Link alla scheda completa:
Pubblicato in: